• 1. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
• 2. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 3. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 4. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 5. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Trifluoromethylbenzenes

Introduction to 4-Chloro-6-Methyl-2-(4-(Trifluoromethyl)phenyl)pyrimidine (CAS No. 125904-05-4)

4-Chloro-6-methyl-2-(4-(trifluoromethyl)phenyl)pyrimidine, with the CAS number 125904-05-4, is a synthetic organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound is characterized by its unique structure, which includes a pyrimidine ring substituted with a chloro group, a methyl group, and a trifluoromethylated phenyl group. These structural features contribute to its potential as a lead compound in the development of novel therapeutic agents.

The pyrimidine core of 4-chloro-6-methyl-2-(4-(trifluoromethyl)phenyl)pyrimidine is a common scaffold in many biologically active molecules, including several FDA-approved drugs. The presence of the chloro and methyl groups enhances the compound's lipophilicity, which can improve its ability to cross biological membranes and reach its target sites. The trifluoromethylated phenyl group, on the other hand, confers additional stability and metabolic resistance, making the compound more suitable for in vivo applications.

Recent studies have explored the potential of 4-chloro-6-methyl-2-(4-(trifluoromethyl)phenyl)pyrimidine in various therapeutic areas. One notable application is in the treatment of cancer. Research has shown that this compound exhibits potent antiproliferative activity against several cancer cell lines, including those derived from breast, lung, and colon cancers. The mechanism of action is believed to involve the inhibition of key enzymes involved in cell proliferation and survival pathways.

In addition to its anticancer properties, 4-chloro-6-methyl-2-(4-(trifluoromethyl)phenyl)pyrimidine has also been investigated for its potential as an antiviral agent. Studies have demonstrated that this compound can effectively inhibit the replication of certain viruses, such as influenza and hepatitis C viruses. The antiviral activity is thought to be mediated through the disruption of viral replication enzymes or the modulation of host cell signaling pathways.

The pharmacokinetic properties of 4-chloro-6-methyl-2-(4-(trifluoromethyl)phenyl)pyrimidine have been extensively studied to optimize its therapeutic potential. Preclinical data indicate that this compound has favorable absorption, distribution, metabolism, and excretion (ADME) profiles. It is well absorbed after oral administration and exhibits good bioavailability. The compound also shows low plasma protein binding, which can enhance its distribution to target tissues.

To further enhance the therapeutic efficacy and safety of 4-chloro-6-methyl-2-(4-(trifluoromethyl)phenyl)pyrimidine, researchers are exploring various prodrug strategies. Prodrugs are inactive derivatives that are converted into their active form in vivo through metabolic processes. This approach can improve the solubility, stability, and target specificity of the compound, thereby reducing potential side effects.

Clinical trials are currently underway to evaluate the safety and efficacy of 4-chloro-6-methyl-2-(4-(trifluoromethyl)phenyl)pyrimidine in human subjects. Early-phase trials have shown promising results, with the compound demonstrating good tolerability and preliminary evidence of therapeutic benefit. However, more extensive studies are needed to fully understand its clinical potential.

In conclusion, 4-chloro-6-methyl-2-(4-(trifluoromethyl)phenyl)pyrimidine (CAS No. 125904-05-4) is a promising compound with diverse biological activities and potential therapeutic applications. Its unique structural features make it an attractive candidate for further development in medicinal chemistry and pharmaceutical research. Ongoing studies will continue to elucidate its mechanisms of action and optimize its use in clinical settings.

• 83217-10-1(4,6-DICHLORO-2-[3-(TRIFLUOROMETHYL)PHENYL]PYRIMIDINE)
• 180606-70-6(4-Chloro-6-methyl-2-(3-methylphenyl)pyrimidine)
• 79382-77-7(4-Chloro-6-methyl-2-(4-methylphenyl)pyrimidine)
• 874988-67-7(Pyrimidine, 4-chloro-2-(2-methyl-4-pyridinyl)-6-(trifluoromethyl)-)
• 659729-09-6(4-Chloro-6-(4-(trifluoromethyl)phenyl)pyrimidine)
• 56302-42-2( )
• 404827-80-1(4-chloro-5,6-dimethyl-2-(2-(trifluoromethyl)phenyl)pyrimidine)
• 404827-82-3(4-chloro-6-methyl-2-[2-(trifluoromethyl)phenyl]pyrimidine)
• 29509-92-0(4-Chloro-6-methyl-2-phenylpyrimidine)
• 204394-70-7(4-Chloro-2-(pyridin-4-yl)-6-(trifluoromethyl)pyrimidine)